Followers | 2773 |
Posts | 77901 |
Boards Moderated | 1 |
Alias Born | 05/10/2007 |
Friday, December 17, 2010 1:44:42 AM
The recent positive recommendation from the FDA advisory panel despite a negative Senate Finance Committee report regarding GSK's behavior, clearly highlights the continued importance of Insulin Sensitizers such as Avandia® and Sucanon® in the ongoing battle against diabetes world wide," said the management of Fero Industries. "We can confidently say that, unlike Avandia®, previous clinical studies have shown that Sucanon® is an effective treatment for Type-II diabetes without adverse cardiovascular risks. To our knowledge, Sucanon® has had no reported issues when it was previously being marketed by the prior owner. Moreover, the formulation of Sucanon® is drastically different from that of Avandia. Sucanon® is an herbal remedy, not a drug. The North American and global potential for Sucanon® is enormous."
Sucanon® is one of only three approved drugs in what is a $5.6 billion dollar market for a class of diabetic medications called "Insulin Sensitizers". Pre-clinical and clinical studies in show that Sucanon® and other insulin sensitizer's lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin.
Sucanon® is currently approved as an Over-The-Counter ("OTC") remedy for Type II diabetes by regulatory authorities in Mexico and will be distributed under an agreement with Merck S.A. de C.V. in Mexico and throughout Latin America. Sucanon® was previously available in Mexico at both Costco and Wal-Mart. Mexico is the eighth largest pharmaceutical market and has one of the largest diabetic populations in the world.
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM